<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036109</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0320</org_study_id>
    <nct_id>NCT05036109</nct_id>
  </id_info>
  <brief_title>DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease</brief_title>
  <official_title>DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To learn if lifestyle changes (such as diet and exercise) combined with daily aspirin and&#xD;
      vitamin D can affect the likelihood of advanced colorectal cancer coming back (recurring)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual&#xD;
      disease after 3 months of optimal lifestyle interventions&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To evaluate the dynamics of ctDNA allele fractions after 3 months of optimal lifestyle To&#xD;
      estimate the recurrence rate at 1 year in subjects who complete 3 months of optimal lifestyle&#xD;
      interventions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual disease</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin, Vitamin D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>by mouth every day for up to 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>by mouth every day for up to 90 days</description>
    <arm_group_label>Aspirin, Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>by mouth every day for up to 90 days</description>
    <arm_group_label>Aspirin, Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.</description>
    <arm_group_label>Aspirin, Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Activity</intervention_name>
    <description>The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly</description>
    <arm_group_label>Aspirin, Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Support Counseling Sessions</intervention_name>
    <description>Patients will undergo a one-on-one counseling session prior to day 1</description>
    <arm_group_label>Aspirin, Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        .-Age â‰¥ 18 years at the time of study entry&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Histologically documented high-risk stage II, stage III, or stage IV colorectal&#xD;
             adenocarcinoma with no evidence of disease following definitive local therapy&#xD;
             (including surgical resection or ablation)&#xD;
&#xD;
          -  No radiographic evidence of disease by contrast enhanced CT chest/abdomen/pelvis&#xD;
&#xD;
          -  Presence of detectable ctDNA mutation that matches mutations found in tumor tissue&#xD;
&#xD;
          -  Completion of all standard of care adjuvant therapy&#xD;
&#xD;
          -  Platelet count &gt;50,000&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Ability to complete all questionnaires involved in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent malignancy under active treatment&#xD;
&#xD;
          -  Known active gastrointestinal bleeding or peptic ulcer disease&#xD;
&#xD;
          -  Known hypersensitivity to vitamin D or aspirin&#xD;
&#xD;
          -  CrCl&lt;30 mL/min within 30 days of starting the intervention&#xD;
&#xD;
          -  Current usage of therapeutic anticoagulation (warfarin, Eliquis, Xarelto)&#xD;
&#xD;
          -  Inability to safely participate in physical activity in the opinion of the treating&#xD;
             oncologist&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Persistent hypercalcemia or conditions predisposing to hypercalcemia (i.e.,&#xD;
             hyperparathyroidism)&#xD;
&#xD;
          -  Known symptomatic genitourinary stones&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Kopetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>scott Kopetz</last_name>
    <phone>(713) 792-2828</phone>
    <email>skopetz@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Kopetz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Scott Kopetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

